Key Points
- Oruka Therapeutics SVP Arjun Agarwal sold 533 shares for approximately $51,035 under a pre-arranged Rule 10b5-1 trading plan, reducing his position by 3.61% to 14,219 shares.
- The sale follows several larger insider transactions, including sales of 9,459 shares in September and 10,000 shares in August, while Oruka shares opened at $93.38 and remain well above their 52-week low.
- Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $133, although the company recently missed quarterly EPS estimates and is expected to post a full-year loss.
Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) SVP Arjun Agarwal sold 533 shares of the business's stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $95.75, for a total transaction of $51,034.75. Following the completion of the transaction, the senior vice president directly owned 14,219 shares of the company's stock, valued at approximately $1,361,469.25. This represents a 3.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Arjun Agarwal also recently made the following trade(s):
- On Tuesday, September 15th, Arjun Agarwal sold 560 shares of Oruka Therapeutics stock. The stock was sold at an average price of $95.71, for a total transaction of $53,597.60.
- On Friday, September 11th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The stock was sold at an average price of $92.23, for a total transaction of $872,403.57.
- On Thursday, August 13th, Arjun Agarwal sold 10,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $106.66, for a total value of $1,066,600.00.
- On Monday, July 13th, Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock. The shares were sold at an average price of $84.63, for a total value of $846,215.37.
Oruka Therapeutics Stock Down 1.7%
Shares of Oruka Therapeutics stock opened at $93.38 on Tuesday. Oruka Therapeutics, Inc. has a fifty-two week low of $14.89 and a fifty-two week high of $115.51. The business's fifty day moving average is $96.58 and its two-hundred day moving average is $74.50. The firm has a market cap of $6.18 billion, a PE ratio of -46.00 and a beta of -0.34.
Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.04). Equities research analysts anticipate that Oruka Therapeutics, Inc. will post -2.42 EPS for the current year.
Institutional Investors Weigh In On Oruka Therapeutics
A number of institutional investors have recently added to or reduced their stakes in ORKA. Nykredit A S purchased a new position in shares of Oruka Therapeutics in the 2nd quarter worth about $29,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Oruka Therapeutics during the 4th quarter worth about $67,000. Orion Capital Management LLC acquired a new stake in Oruka Therapeutics during the 2nd quarter worth approximately $91,000. Royal Bank of Canada increased its position in Oruka Therapeutics by 178.5% during the 1st quarter. Royal Bank of Canada now owns 3,172 shares of the company's stock worth $155,000 after purchasing an additional 2,033 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its position in Oruka Therapeutics by 119.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,186 shares of the company's stock worth $156,000 after purchasing an additional 1,736 shares in the last quarter. Hedge funds and other institutional investors own 56.44% of the company's stock.
Wall Street Analysts Forecast Growth
Several research firms have commented on ORKA. BTIG Research restated a "buy" rating and issued a $151.00 price target on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Weiss Ratings raised shares of Oruka Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, July 15th. Wall Street Zen cut shares of Oruka Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, August 16th. UBS Group upped their price target on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the stock a "buy" rating in a research report on Wednesday, July 1st. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $180.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Oruka Therapeutics has an average rating of "Moderate Buy" and an average price target of $133.00.
View Our Latest Stock Report on Oruka Therapeutics
About Oruka Therapeutics
(
Get Free Report)
Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company's research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.
Oruka's initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
